Tender detail
Open-house discount agreements for biologics 2026-09 – etanercept
Summary
The participating health insurance funds seek to conclude rebate agreements with pharmaceutical companies for the active substance etanercept under the open-house procedure. The agreements use uniform terms, involve no individual negotiations and do not grant exclusivity. The contract period begins on 1 May 2026 and ends no later than 30 April 2028, with a maximum duration of 24 months; participation is possible at any time during the contract period.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.